Selecta/Sobi Gout Drug Numerically, Not Significantly, Beat Krystexxa
SEL-212 Bested Horizon’s Drug But A New Standard Is Emerging
Executive Summary
Analysts have mixed opinions about whether a Phase IIb study of SEL-212, which Selecta recently licensed to Sobi, helps the drug’s commercial potential versus Horizon’s Krystexxa.
You may also be interested in...
Sobi Loses Private Equity Buyout
An $8bn public-to-private takeout by two private equity firms of the Swedish rare disease specialist collapses because total tenders to the offer fell below a 90% threshold.
Sobi To Go Private In $8.1bn Buyout That Appreciates Growth Strategy
Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.
Horizon And Arrowhead To Develop RNAi Therapeutic For Gout
Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.